The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Jul. 06, 2021
Filed:
Oct. 22, 2019
Applicant:
Medivation Technologies Llc, New York, NY (US);
Inventors:
Roopa Rai, San Francisco, CA (US);
Sarvajit Chakravarty, San Francisco, CA (US);
Brahmam Pujala, Noida, IN;
Bharat Uttam Shinde, Noida, IN;
Anjan Kumar Nayak, Noida, IN;
Anil Kumar Agarwal, Noida, IN;
Sreekanth A. Ramachandran, Noida, IN;
Son Minh Pham, San Francisco, CA (US);
Assignee:
Medivation Technologies LLC, New York, NY (US);
Attorney:
Primary Examiner:
Int. Cl.
CPC ...
C07D 401/12 (2006.01); C07D 401/14 (2006.01); C07D 405/14 (2006.01); C07D 413/14 (2006.01); C07D 471/04 (2006.01); C07D 487/04 (2006.01); A61K 31/4439 (2006.01); A61K 31/444 (2006.01); A61K 31/4545 (2006.01); A61K 31/4709 (2006.01); C07D 213/72 (2006.01); C07D 213/73 (2006.01); C07D 213/82 (2006.01); A61K 45/06 (2006.01); A61K 31/506 (2006.01);
U.S. Cl.
CPC ...
C07D 401/12 (2013.01); A61K 31/444 (2013.01); A61K 31/4439 (2013.01); A61K 31/4545 (2013.01); A61K 31/4709 (2013.01); A61K 31/506 (2013.01); A61K 45/06 (2013.01); C07D 213/72 (2013.01); C07D 213/73 (2013.01); C07D 213/82 (2013.01); C07D 401/14 (2013.01); C07D 405/14 (2013.01); C07D 413/14 (2013.01); C07D 471/04 (2013.01); C07D 487/04 (2013.01);
Abstract
This disclosure provides compounds and compositions and methods of using those compounds and compositions to treat diseases and disorders associated with excessive transforming growth factor-beta (TGFβ) activity. This disclosure also provides methods of using the compounds in combination with one or more cancer immunotherapies.